How Drug-Industry Lobbyists Got Their Way on Health Care

Time by Karen Tumulty, Michael Scherer | Oct. 22, 2009 (Special Report)

It's understandable the drugmakers would want a roll-call accounting of who their friends and enemies are, considering the size of the investment they are making on Capitol Hill: in the first six months of this year alone, drug and biotech companies and their trade associations spent more than $110 million — that's about $609,000 a day — to influence lawmakers, according to figures compiled by the nonpartisan watchdog group Center for Responsive ... Full Story »

Posted by Kaizar Campwala - via Ellen Miller, Huffington Post (Health Care)

More Info

Tags Help
Subjects: Politics, U.S., Health, Business
Topics: Health Care, Pharmaceuticals, Lobbying, Money and Politics, U.S. Congress
Stats Help
# Tweets: 2 (as of 2009-10-22)
Editorial Help
Posted by: via Ellen Miller - Oct 22, 2009 - 12:24 PM PDT
Reviewed by: Kaizar Campwala (review), Theresa Dark (review), Ben Ross (review)
Edit Lock: This story can be edited
Edited by: Kaizar Campwala - Oct 25, 2009 - 7:41 AM PDT
Like | | | Comments

To:


Separate email addresses with commas.
25 recipients max.

Note:

Related Comments: Health Care (7)

Reviews

Show All | Notes | Comments | Quotes | Links
N638965977_3994_thumb
3.4
 by Ben Ross - Oct. 27, 2009

Takes a while to get the info across...leaves out facts which many would like to keep hidden. Not bad for TIME....does not mention any history of patent law history or intent.

See Full Review » (11 answers)
Member_photo_thumb
4.0
 by Kaizar Campwala - Oct. 25, 2009
Kaizar posted this story.
See Full Review » (3 answers)
Silhouette_sml
4.2
 by Theresa Dark - Oct. 25, 2009

Karen Tumulty and Michael Scherer's headline definitely grabbed my attention. The proceeding introduction (hook) into the article continued to keep my interest. The next couple of paragraphs talk about the significance of the hook and sets up the reader for the caveat. Both journalists do a good job of giving relevant points supporting the article. They also have several links providing information on pertinent data relating to the article. The conclusion of the article gives several ... More »

See Full Review » (19 answers)

Comments on this story Help (BETA)

Sort by: Oldest | Newest Hide All Replies
NT Rating | My Rating

Ratings

3.8

Good
from 3 reviews (38% confidence)
Quality
3.8
Facts
4.0
Fairness
3.5
Information
5.0
Insight
4.0
Sourcing
3.0
Style
3.5
Accuracy
4.0
Balance
4.0
Context
4.0
Depth
3.5
Enterprise
4.0
Expertise
3.0
Originality
4.0
Relevance
4.5
Transparency
4.0
Responsibility
4.0
Popularity
3.7
Recommendation
4.3
Credibility
3.7
# Reviews
1.5
# Views
5.0
# Likes
1.0
# Emails
1.0
More
How our ratings work »
(See these related stories.)

Links Help

No links yet. Please review this story to add some!